SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors.

Autor: Palmer T; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland.; Convergence Institute, Johns Hopkins University, Baltimore, Maryland., Kessler MD; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Shao XM; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland., Balan A; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland., Yarchoan M; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Zaidi N; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Lopez-Vidal TY; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Biochemistry, Cellular and Molecular Biology (BCMB) Graduate Program, Johns Hopkins University School of Medicine, Baltimore, Maryland., Saeed AM; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Gore J; Department of Otorhinolaryngology-Head and Neck Surgery, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland., Azad NS; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Jaffee EM; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Favorov AV; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Laboratory of Systems Biology and Computational Genetics, Vavilov Institute of General Genetics, Moscow, Russia., Anagnostou V; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Karchin R; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland., Gaykalova DA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Department of Otorhinolaryngology-Head and Neck Surgery, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland., Fertig EJ; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland.; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, Maryland., Danilova L; Convergence Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Jazyk: angličtina
Zdroj: Cancer research communications [Cancer Res Commun] 2024 Dec 01; Vol. 4 (12), pp. 3137-3150.
DOI: 10.1158/2767-9764.CRC-23-0309
Abstrakt: Significance: SpliceMutr shows that splicing antigenicity changes in response to ICI therapies and that native modulation of the splicing machinery through mutations increases the contribution of splicing to the neoantigen load of some The Cancer Genome Atlas cancer subtypes. Future studies of the relationship between splicing antigenicity and immune checkpoint inhibitor response pan-cancer are essential to establish the interplay between antigen heterogeneity and immunotherapy regimen on patient response.
(©2024 The Authors; Published by the American Association for Cancer Research.)
Databáze: MEDLINE